Technology

As AI rapidly reshapes drug development and clinical operations, industry leaders say transparency, governance, and strong data foundations will determine whether the technology accelerates innovation or stalls under regulatory and operational pressure.

The gap between AI’s abilities and how people use could be about capability, but it’s also about confidence, belief and mindset.

As the AI-first era matures, life sciences leaders must pivot from narrow, task-specific models toward integrated, interpretable frameworks that transform biological complexity into a sustainable competitive advantage.

As the pharma industry continues to experiment with AI implantation, certain areas are showing more promise than others.

Most medical digital pilots are designed for success in controlled conditions.

As therapeutic complexity increases, life sciences companies should cultivate open mindsets toward innovative data sources beyond traditional claims and electronic medical record data.

What’s missing from many care strategies today is the actual voice of the patient.

The collaboration will employ Iambi’s AI drug discovery technology to advance several small molecule programs in oncology, gastrointestinal, and inflammatory diseases.

By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI platforms are leveling the playing field by enabling lean teams to de-risk clinical strategy, strengthen fundraising narratives, and make faster, more confident decisions across the development lifecycle.

Dave Carey, CEO, Preceptis Medical and Michael Monovoukas, CEO, co-founder, AcuityMD note the importance of shifting ear tube procedures into the office, reducing anesthesia risk, and how AI-driven data and adaptive commercial strategies are becoming critical to scaling new medtech innovations.

Poor visualization techniques can oversimplify reality and make data less potent.

Anders Romare, Advisory Board Member, causaLens, and former Novo Nordisk CDIO, outlines why artificial intelligence represents a structural turning point for the pharmaceutical industry.

The AI dilemma facing biopharma—and what’s at risk.

In the third part of her conversation with PharmExec, Trialynx founder and CEO Angela Schwab discusses the causes and solutions for high failure rates in clinical trials.

Trialynx founder and CEO Angela Schwab continues her conversation with PharmExec and explains the effective ways that AI is being used to tackle common problems with clinical trial design.

Pharmaceutical manufacturers must address the question of how exactly does value get created and destroyed inside these organizations and how will AI fundamentally shift that equation?

AI’s transformative potential in clinical development relies on the industry's ability to rebuild its fractured data infrastructure.

Outlining the big questions and considerations for pharma companies in determining their readiness for this transformation—and achieving true “AI Advanced” status.

The filing follows the completion of a pivotal study targeting abdominal conditions.

New technologies are helping the industry move toward more predictive and humane approaches.

Start managing the transformation now to secure every benefit.

From CRM saturation to commercial orchestration.

Eli Lilly and NVIDIA unveil a groundbreaking AI supercomputer, revolutionizing drug discovery and accelerating patient care through advanced technology.

AI transforms pharmaceutical operations by automating workflows, ensuring transparency, and enhancing compliance, driving efficiency and innovation in healthcare.

Peptilogics Founder and CEO, Jonathan Steckbeck, explained that PLG0206’s membrane-active mechanism enables it to destroy both active and dormant biofilm bacteria overcoming a key limitation of traditional antibiotics.